UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~December~~February 3103, ~~2019~~2020

SLEEPAID HOLDING CO.

(Exact Name of Registrant as Specified in its Charter)

Nevada	000-55446	47-3785730
(State or Other Jurisdictionof Incorporation)	(Commission FileNumber)	(IRS EmployerIdentification No.)
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)

Rm 10 1/F Wellborne Commercial ~~Centre~~Centre8 Java RoadNorth Point, Hong Kong (Address of Principal Executive Office) (Zip Code)

8 Java Road

North Point, Hong Kong

(Address of Principal Executive Office) (Zip Code)

Registrant’s telephone number, including area code: (852) 2806-2312

~~_____________________________________________~~____________________________________________

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~ITEM 15.0102. ~~Entry~~DEPARTURE ~~into~~OF aDIRECTORS ~~Material~~OR ~~Definitive~~PRINCIPAL ~~Agreement~~OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS

On December 3131th, 2019, ~~Sleepaid~~Ms. ~~Holding~~Qiuli ~~Co.~~Chen, (the ~~“Company”)~~Chief ~~entered~~Executive ~~into~~Director, aand ~~Shares~~Chief ~~Trading~~Financial ~~Agreement~~Director of Sleepaid Holding Company (the “~~Agreement~~Company”) ~~agreed~~has tosubmitted ~~sell~~her ~~all~~resignation ~~the~~for ~~shares~~her ofpersonal ~~its~~accord ~~subsidiary,~~to ~~Nice~~the ~~Great~~board. ~~International~~On ~~Limited~~3rd ~~(“Nice~~of ~~Great”) to a third-party buyer~~February, ~~Cheung~~the ~~Kuen~~board ~~Harry~~accepted Ms. AsChen’s aresignation, ~~result of this Agreement~~simultaneously, the ~~Company~~board noappointed ~~longer~~Mr. ~~owns~~Lowell ~~its~~Holden ~~subsidiary,~~as ~~Nice~~the ~~Great.~~Chief ~~The~~Executive ~~Company~~Director, ~~received~~Chief ~~total~~Financial ~~consideration~~Director of ~~HKD~~the ~~30,000~~Company.

On ~~December~~May 319th, 2019, ~~the~~Lowell ~~Agreement~~Holden ~~closed~~was appointed as a director of Sleepaid. Mr. Holden has owned and ~~ownership~~operated ~~transferred~~his own consulting firm, LS Enterprises, Inc., which provides business consulting, accounting and other services to businesses, since 1983. Mr. Holden has a broad range of business experience including managing, securing financing, structuring of transactions, and is experienced and knowledgeable in managing relationships with customers, financing institutions and stockholders. Presently Mr. Holden serves as the ~~new~~director ~~owners~~and Chief Financial officer of Nascent Biotech Inc. (“NBIO”), Chief Financial Officer of Skkynet Cloud Systems, Inc. (“SKKY”), Chief Financial Officer and director of EMR Technology, and Chief Executive Officer and director of PTS, Inc. (“PTSH”). Mr. Holden also has a background in assisting companies in fulfilling their financial auditing and SEC reporting requirements. Mr. Lowell Holden has a Bachelor of Science degree from Iowa State University.

~~Item~~ 2~~.01. Completion of Acquisition or Disposition of Assets~~

~~The information provided in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference~~SIGNATURES

~~Item~~Pursuant ~~9.01~~to ~~Financial~~the ~~Statements~~requirements of the Securities and ~~Exhibits~~Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

(d) Exhibits

	SLEEPAID HOLDING CO.

Date: February 3^rd, 2020	By:	/s/ Lowell Holden
		Lowell Holden, CEO

ExhibitNumber		Exhibit Description
10.1		Shares Trading Agreement

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	SLEEPAID HOLDING CO.
Date: December 31, 2019	By:	/s/ Qiuli Chen
		Qiuli Chen, CEO

Filing Compare · Sleepaid Holding Co.